Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4960509 | 0.80 | CYP19A1 (0.35) | CYP19A1 | |
| SCHEMBL4033449 | 0.79 | CYP19A1 (0.46) | CYP19A1ALDH1A1P2RX7 | |
| SCHEMBL25793112 | 0.69 | POLB (0.32) | CYP19A1ALDH1A1 | |
| SCHEMBL20797467 | 0.69 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL3275984 | 0.68 | ALDH1A1 (0.36) | ALDH1A1P2RX7 | |
| SCHEMBL25159753 | 0.67 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL17581664 | 0.65 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL3404326 | 0.65 | TLR8 (0.39) | ALDH1A1 | |
| SCHEMBL6856055 | 0.65 | HDAC1 (0.32) | ALDH1A1 | |
| SCHEMBL13072298 | 0.64 | CYP19A1 (0.46) | CYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725241-A4 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-03-25 | — | — | EP | claimed |
| EP-1725241-A1 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | claimed |
| WO-2005094835-A1 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | claimed |
| EP-1725544-B1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7514458-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514458-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514458-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1725241-A4 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-03-25 | — | — | EP | disclosed |
| EP-1887003-A1 | 3-[4-HETEROCYCLYL -1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | COGAN DEREK | 2007-06-21 | — | — | US | disclosed |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | COGAN DEREK | 2007-06-21 | — | — | US | disclosed |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | COGAN DEREK | 2007-06-21 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1725241-A1 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2005094835-A1 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | TNF, IL6, IL1A | CYP19A1 2211/4885ALDH1A1 278/4885P2RX7 1065/4885 |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL1A | CYP19A1 2211/4885ALDH1A1 278/4885P2RX7 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.